BRPI0606165A2 - método de indução de uma resposta imunológica de célula t de memória contra pelo menos um antìgeno em um paciente humano, uso de uma composição imunogênica que compreende um vetor de vìrus de infecção virulenta não-replicante ou emparelhado de replicação que expressa o produto de tradução de um gene de ag85a micobacterial, uso de um antìgeno na manufatura de um medicamento para o tratamento de uma doença em um paciente mediante a indução de uma resposta imunológica de célula t de memória central e vacina vetorada - Google Patents
método de indução de uma resposta imunológica de célula t de memória contra pelo menos um antìgeno em um paciente humano, uso de uma composição imunogênica que compreende um vetor de vìrus de infecção virulenta não-replicante ou emparelhado de replicação que expressa o produto de tradução de um gene de ag85a micobacterial, uso de um antìgeno na manufatura de um medicamento para o tratamento de uma doença em um paciente mediante a indução de uma resposta imunológica de célula t de memória central e vacina vetoradaInfo
- Publication number
- BRPI0606165A2 BRPI0606165A2 BRPI0606165-6A BRPI0606165A BRPI0606165A2 BR PI0606165 A2 BRPI0606165 A2 BR PI0606165A2 BR PI0606165 A BRPI0606165 A BR PI0606165A BR PI0606165 A2 BRPI0606165 A2 BR PI0606165A2
- Authority
- BR
- Brazil
- Prior art keywords
- antigen
- inducing
- immune response
- cell immune
- patient
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 7
- 108091007433 antigens Proteins 0.000 title abstract 7
- 102000036639 antigens Human genes 0.000 title abstract 7
- 230000028993 immune response Effects 0.000 title abstract 5
- 230000001939 inductive effect Effects 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 4
- 239000013598 vector Substances 0.000 title abstract 4
- 230000002163 immunogen Effects 0.000 title abstract 3
- 208000015181 infectious disease Diseases 0.000 title abstract 3
- 210000003071 memory t lymphocyte Anatomy 0.000 title abstract 3
- 108090000623 proteins and genes Proteins 0.000 title abstract 3
- 230000003362 replicative effect Effects 0.000 title abstract 3
- 241000700605 Viruses Species 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title 1
- 229940126580 vector vaccine Drugs 0.000 title 1
- 229960005486 vaccine Drugs 0.000 abstract 3
- 210000004027 cell Anatomy 0.000 abstract 2
- 230000005867 T cell response Effects 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000006698 induction Effects 0.000 abstract 1
- 229940126601 medicinal product Drugs 0.000 abstract 1
- 241000701161 unidentified adenovirus Species 0.000 abstract 1
- 239000013603 viral vector Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
MéTODO DE INDUçãO DE UMA RESPOSTA IMUNOLóGICA DE CéLULA T DE MEMóRIA CONTRA PELO MENOS UM ANTìGENO EM UM PACIENTE HUMANO, USO DE UMA COMPOSIçãO IMUNOGêNICA QUE COMPREENDE UM VETOR DE VìRUS DE INFECçãO VIRULENTA NãO-REPLICANTE OU EMPARELHADO DE REPLICAçãO QUE EXPRESSA O PRODUTO DE TRADUçãO DE UM GENE DE AG85A MICOBACTERIAL, USO DE UM ANTìGENO NA MANUFATURA DE UM MEDICAMENTO PARA O TRATAMENTO DE UMA DOENçA EM UM PACIENTE MEDIANTE A INDUçãO DE UMA RESPOSTA IMUNOLóGICA DE CéLULA T DE MEMóRIA CENTRAL E VACINA VETORADA. Trata-se de um método para gerar uma resposta imunológica das células T em um hospedeiro, o qual envolve a administraçào de uma vacina vetorizada que compreende um vetor viral n~o-replicante ou de replicação danificada que expressa o produto da traduçào de um gene 85A do antígeno micobacteriano. As vacinas vetorizadas e os usos das mesmas também são apresentados. Também é apresentado um método para induzir uma resposta das células T de memória de CD8 e CD4 contra um antígeno utilizando um vetor de adenovírus que expressa um antígeno ou um fragmento imunogênico do mesmo.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0500102.9A GB0500102D0 (en) | 2005-01-05 | 2005-01-05 | Method for generating a memory t cell response |
| US64980405P | 2005-02-03 | 2005-02-03 | |
| PCT/GB2006/000023 WO2006072787A1 (en) | 2005-01-05 | 2006-01-05 | Compositions for immunizing against mycobacterium |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0606165A2 true BRPI0606165A2 (pt) | 2009-06-02 |
Family
ID=36062509
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0606165-6A BRPI0606165A2 (pt) | 2005-01-05 | 2006-01-05 | método de indução de uma resposta imunológica de célula t de memória contra pelo menos um antìgeno em um paciente humano, uso de uma composição imunogênica que compreende um vetor de vìrus de infecção virulenta não-replicante ou emparelhado de replicação que expressa o produto de tradução de um gene de ag85a micobacterial, uso de um antìgeno na manufatura de um medicamento para o tratamento de uma doença em um paciente mediante a indução de uma resposta imunológica de célula t de memória central e vacina vetorada |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP1833507B1 (pt) |
| JP (2) | JP2008526823A (pt) |
| KR (1) | KR20070108518A (pt) |
| AP (1) | AP2007004059A0 (pt) |
| AU (1) | AU2006204382B2 (pt) |
| BR (1) | BRPI0606165A2 (pt) |
| CA (1) | CA2592756A1 (pt) |
| CY (1) | CY1111549T1 (pt) |
| EA (1) | EA012436B1 (pt) |
| HR (1) | HRP20110402T1 (pt) |
| IL (2) | IL184414A (pt) |
| MA (1) | MA29244B1 (pt) |
| MX (1) | MX2007008182A (pt) |
| NZ (1) | NZ560468A (pt) |
| PL (1) | PL1833507T3 (pt) |
| WO (1) | WO2006072787A1 (pt) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5461776B2 (ja) * | 2004-12-01 | 2014-04-02 | エーラス グローバル ティービー ワクチン ファウンデーション | マイコバクテリウムのエレクトロポレーションおよびマイコバクテリア中における抗原類の過剰発現 |
| US8691502B2 (en) | 2008-10-31 | 2014-04-08 | Tremrx, Inc. | T-cell vaccination with viral vectors via mechanical epidermal disruption |
| KR20170072366A (ko) * | 2009-04-24 | 2017-06-26 | 스태튼스 세룸 인스티튜트 | 재활성화를 예방하기 위한 결핵 백신 |
| CA2793151C (en) * | 2010-03-19 | 2018-05-22 | Red Flag Diagnostics Gmbh | In vitro process for the quick determination of a patient's status relating to infection with mycobacterium tuberculosis |
| WO2014009438A2 (en) | 2012-07-10 | 2014-01-16 | Transgene Sa | Mycobacterial antigen vaccine |
| US10765731B2 (en) * | 2014-01-09 | 2020-09-08 | Transgene Sa | Fusion of heterooligomeric mycobacterial antigens |
| EP3224384A4 (en) * | 2014-11-25 | 2018-04-18 | Adaptive Biotechnologies Corp. | Characterization of adaptive immune response to vaccination or infection using immune repertoire sequencing |
| RU2665817C1 (ru) * | 2017-10-25 | 2018-09-04 | федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации | Вакцина рекомбинантная противотуберкулезная и адъювант для нее |
| US12398179B2 (en) | 2019-03-14 | 2025-08-26 | Sanford Burnham Prebys Medical Discovery Institute | Nanomolar peptides and derivatives to differentially modulate ephrin receptors |
-
2006
- 2006-01-05 NZ NZ560468A patent/NZ560468A/en not_active IP Right Cessation
- 2006-01-05 AU AU2006204382A patent/AU2006204382B2/en not_active Ceased
- 2006-01-05 CA CA002592756A patent/CA2592756A1/en not_active Abandoned
- 2006-01-05 PL PL06700223T patent/PL1833507T3/pl unknown
- 2006-01-05 EA EA200701440A patent/EA012436B1/ru not_active IP Right Cessation
- 2006-01-05 WO PCT/GB2006/000023 patent/WO2006072787A1/en not_active Ceased
- 2006-01-05 AP AP2007004059A patent/AP2007004059A0/xx unknown
- 2006-01-05 MX MX2007008182A patent/MX2007008182A/es not_active Application Discontinuation
- 2006-01-05 BR BRPI0606165-6A patent/BRPI0606165A2/pt not_active IP Right Cessation
- 2006-01-05 KR KR1020077018013A patent/KR20070108518A/ko not_active Abandoned
- 2006-01-05 HR HR20110402T patent/HRP20110402T1/hr unknown
- 2006-01-05 JP JP2007549950A patent/JP2008526823A/ja active Pending
- 2006-01-05 EP EP06700223A patent/EP1833507B1/en not_active Expired - Lifetime
-
2007
- 2007-07-04 IL IL184414A patent/IL184414A/en not_active IP Right Cessation
- 2007-08-03 MA MA30124A patent/MA29244B1/fr unknown
-
2011
- 2011-06-10 CY CY20111100558T patent/CY1111549T1/el unknown
- 2011-12-27 IL IL217235A patent/IL217235A0/en unknown
-
2012
- 2012-08-24 JP JP2012184893A patent/JP2013010775A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2006204382A1 (en) | 2006-07-13 |
| JP2013010775A (ja) | 2013-01-17 |
| MA29244B1 (fr) | 2008-02-01 |
| HRP20110402T1 (hr) | 2011-07-31 |
| PL1833507T3 (pl) | 2011-08-31 |
| JP2008526823A (ja) | 2008-07-24 |
| IL184414A0 (en) | 2007-10-31 |
| IL184414A (en) | 2012-01-31 |
| MX2007008182A (es) | 2008-02-19 |
| KR20070108518A (ko) | 2007-11-12 |
| AU2006204382B2 (en) | 2011-05-12 |
| EA012436B1 (ru) | 2009-10-30 |
| AP2007004059A0 (en) | 2007-08-31 |
| CA2592756A1 (en) | 2006-07-13 |
| CY1111549T1 (el) | 2015-08-05 |
| WO2006072787A1 (en) | 2006-07-13 |
| IL217235A0 (en) | 2012-01-31 |
| EP1833507A1 (en) | 2007-09-19 |
| WO2006072787A8 (en) | 2006-09-14 |
| EA200701440A1 (ru) | 2008-02-28 |
| NZ560468A (en) | 2010-05-28 |
| EP1833507B1 (en) | 2011-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Delany et al. | Vaccines for the 21st century | |
| Vetter et al. | Understanding modern-day vaccines: what you need to know | |
| Pillet et al. | A plant-derived quadrivalent virus like particle influenza vaccine induces cross-reactive antibody and T cell response in healthy adults | |
| Ingolotti et al. | DNA vaccines for targeting bacterial infections | |
| Mount et al. | Combination of adjuvants: the future of vaccine design | |
| BR0311995A (pt) | Partìculas semelhantes a vìrus empacotadas para o uso como adjuvantes: método de preparação e uso | |
| TW200722101A (en) | Novel composition | |
| Holvast et al. | Influenza vaccination in systemic lupus erythematosus: safe and protective? | |
| EA201171032A1 (ru) | Схемы лечения с помощью вакцины против гриппа, связанного с пандемическими штаммами | |
| BRPI0508813A (pt) | vacinas de combinação com baixa dose de conjugado de hib | |
| Plotkin | Six revolutions in vaccinology | |
| BR112015022582A2 (pt) | molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo | |
| CY1111549T1 (el) | Συνθεσεις για ανοσοποιηση εναντι μυκοβακτηριδιου | |
| KB et al. | Vaccine and vaccination as a part of human life: In view of COVID‐19 | |
| Xing et al. | New approaches to TB vaccination | |
| BR112013001946A2 (pt) | vírus varicela zoster inativado, composição farmacêutica, método para preparar um vírus varicela zoster inativado, vacina, e, método para o tratamento de herpes zoster em um indivíduo | |
| Garg et al. | A review on COVID-19 vaccinations | |
| Depelsenaire et al. | Introduction to vaccines and vaccination | |
| ZA200706389B (en) | Compositions for immunizing against mycobacterium | |
| Chavda et al. | History of vaccination | |
| BR0213656A (pt) | composição, método para a obtenção de uma resposta imune à tênia, método para vacinar um mamìfero contra tênia, vacina, método para pemitir a vacinação, métodos para a redução de perda sangüìnea, para a redução do tamanho da tênia e para a redução de aflição por tênia em um paciente infectado com tênia, antìgeno recombinante sintético e antìgeno | |
| Kajal et al. | From ancient remedies to modern miracles: tracing the evolution of vaccines and their impact on public health | |
| Singh | Pros and cons of COVID-19 vaccines and vaccination | |
| MUTLA et al. | The Change Complete Blood Count and Other Inflammatory Markers Before and After Sinopharm Coronavirus Vaccine | |
| JP2010529166A5 (pt) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 9A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2287 DE 04/11/2014. |